Skip to main content
C

CHIMERIC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · CHM ISIN · AU0000121576 ASX Professional, scientific and technical activities
Filings indexed 502 across all filing types
Latest filing 2026-02-24 Regulatory Filings
Country AU Australia
Listing ASX CHM

About CHIMERIC THERAPEUTICS LIMITED

https://www.chimerictherapeutics.com

Chimeric Therapeutics Limited is a clinical-stage cell therapy company focused on the development and commercialization of innovative oncology treatments. The company specializes in chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies designed to target solid tumors and hematologic malignancies. Its lead candidate, CHM 1101 (CLTX CAR T), is a first-in-class therapy utilizing chlorotoxin to target glioblastoma. Additionally, the company is developing CHM 2101, a CDH17-targeted CAR T-cell therapy for gastrointestinal cancers, and the CORE-NK platform, which provides a foundation for off-the-shelf NK cell therapies. By leveraging advanced cellular engineering, Chimeric Therapeutics aims to address significant unmet needs in cancer care through precision medicine and novel therapeutic platforms.

Recent filings

Filing Released Lang Actions
Update - Proposed issue of securities - CHM 9 pages 32.1KB
Regulatory Filings
2026-02-24 English
Proposed issue of securities - CHM 5 pages 19.0KB
Regulatory Filings
2026-02-24 English
Revised response to ASX Query Letter 10 pages 1.7MB
Regulatory Filings
2026-02-24 English
Board and management update 3 pages 216.7KB
Regulatory Filings
2026-02-15 English
Initial Director's Interest Notice (BG) 2 pages 255.1KB
Regulatory Filings
2026-02-15 English
CHM CDH17 advances to Dose Level 3 3 pages 197.6KB
Regulatory Filings
2026-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.